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ABSTRACT
Objective Uncovering the dominant molecular
deregulation among the multitude of pathways
implicated in aggressive prostate cancer is essential to
intelligently developing targeted therapies. Paradoxically,
published prostate cancer gene expression signatures of
poor prognosis share little overlap and thus do not reveal
shared mechanisms. The authors hypothesize that, by
analyzing gene signatures with quantitative models of
proteineprotein interactions, key pathways will be
elucidated and shown to be shared.
Design The authors statistically prioritized common
interactors between established cancer genes and genes
from each prostate cancer signature of poor prognosis
independently via a previously validated single protein
analysis of network (SPAN) methodology. Additionally,
they computationally identiﬁed pathways among the
aggregated interactors across signatures and validated
them using a similarity metric and patient survival.
Measurement Using an information-theoretic metric,
the authors assessed the mechanistic similarity of the
interactor signature. Its prognostic ability was assessed
in an independent cohort of 198 patients with
high-Gleason prostate cancer using KaplaneMeier
analysis.
Results Of the 13 prostate cancer signatures that were
evaluated, eight interacted signiﬁcantly with established
cancer genes (false discovery rate <5%) and generated
a 42-gene interactor signature that showed the highest
mechanistic similarity (p<0.0001). Via parameter-free
unsupervised classiﬁcation, the interactor signature
dichotomized the independent prostate cancer cohort
with a signiﬁcant survival difference (p¼0.009).
Interpretation of the network not only recapitulated
phosphatidylinositol-3 kinase/NF-kB signaling, but also
highlighted less well established relevant pathways such
as the Janus kinase 2 cascade.
Conclusions SPAN methodolgy provides a robust
means of abstracting disparate prostate cancer gene
expression signatures into clinically useful, prioritized
pathways as well as useful mechanistic pathways.
INTRODUCTION
Gene signatures provide a glimpse into critical
molecular pathways, as they essentially serve as
a bridge between clinical phenotypes and genomics.
As deﬁned by Richard Simon, ‘a multigene expres-
sion signature classiﬁer is a function that provides
a classiﬁcation of a tumor based on the expression
levels of the component genes. The classes are often
good-risk or poor-risk, but classiﬁers can be deﬁned
to distinguish any set of classes for which a training
set of cases exist for each class.
1’ These signatures
have traditionally been derived by examining the
differential expression of mRNA from discrete
cancer states such as tumor versus normal tissue or
high-grade versus low-grade tumors. Beginning over
a decade ago with the identiﬁcation of poor-risk
breast cancer gene sets,
23these gene signatures
have rapidly proliferated to the point where nearly
1000 entries exist in a gene signature database
established to catalog them.
4 Surprisingly, despite
their proliferation, few of these signatures have
been commercialized and adopted by the medical
community. In the USA, only one product in breast
cancer, OncotypeDX, has achieved widespread
adoption
5; however, newer tests such as a ‘tumor of
origin’ assay
6 for cancers of unknown primary may
gain in popularity. In contrast, biomarkers such as
prostate-speciﬁc antigen (PSA) in prostate cancer,
HER2/Neu in breast cancer, and epidermal growth
factor receptor (EGFR) in colon cancer have enjoyed
rapid usage among practitioners with a multitude
of clinical trials.
Indeed, the vast majority of biomarkers are
functionally and biologically understood, in stark
contrast with gene signatures. Moreover,
biomarkers tend to be single-pathway-speciﬁc,
whereas gene signatures may span multiple mech-
anisms. To add to the confusion, genes constituting
distinct signatures are rarely shared among gene
signatures even though they paradoxically occupy
a common prognostic space.
7 Their similar
efﬁciency in predicting poor clinical outcomes in
new cohorts has led some observers such as Joan
Massague in his 2007 New England Journal of
Medicine editorial to call for research into ‘sorting
out’ these gene signatures and elucidating their
common overlap.
8 Thus a critical problem for those
in oncology has been determining whether these
disjointed genetic signatures can ‘jointly’ provide
a uniﬁed mechanistic rationale bridging both gene
expression and clinical outcomes.
To address this challenge, we have previously
demonstrated that, by aggregating different,
published genetic signatures of poor prognosis, we
can reveal shared molecular pathwaysdfor
example, excess direct interactions with oncogenes
and tumor suppressorsdthrough the application of
a network modeling technique termed single
protein analysis of networks (SPAN).
9 SPAN,
previously validated,
10 takes advantage of
proteineprotein interaction networks that have
been used to generate robust clinical predictions in
other tumor types.
91 1In essence, SPAN uses as
< Additional materials are
published online only. To view
these ﬁles please visit the
journal online (www.jamia.org).
1Department of Medicine,
Sections of
Hematology/Oncology,
University of Chicago, Chicago,
Illinois, USA
2Genetic Medicine of the
Department of Medicine,
University of Chicago, Chicago,
Illinois, USA
3Institute of Genomics and
Systems Biology, University of
Chicago, Chicago, Illinois, USA
4Computational Institute,
University of Chicago, Chicago,
Illinois, USA
Correspondence to
Yves A Lussier, Center for
Biomedical Informatics, 5841
South Maryland Ave, MC 6091,
Chicago, IL 60637-1470, USA;
ylussier@medicine.bsd.
uchicago.edu
Received 11 February 2011
Accepted 17 April 2011
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
jamia.bmj.com/site/about/
unlocked.xhtml
392 J Am Med Inform Assoc 2011;18:392e402. doi:10.1136/amiajnl-2011-000178
Research and applicationsinput a set of uncategorized protein interactions; as output,
SPAN returns proteins that are more connected than can be
expected by chance. The advantage of SPAN over purely
expression- or literature-based methods of prioritization is that
it will detect important proteins even if they are not overtly
modiﬁed or ampliﬁed.
9 Thus SPAN provides critical information
that may not be accessible through expression data alone.
In this paper, we turn our attention to prostate cancer, as it
faces a similar data prioritization problem. The treatment of
prostate cancer has historically been centered around deregula-
tion of the androgen receptor (AR) to effectively eliminate the
effects of testosterone, the ligand for the AR. However, despite
AR-speciﬁc targeted therapy, most patients eventually develop
resistance to these agents. Consequently, multiple alternative
pathways of ‘poor prognosis’ have been studied for therapeutic
targeting, as many molecular mechanisms have been implicated
in AR cross-talk, such as the Janus kinase (JAK)/STAT
12 and
platelet-derived growth factor (PDGF) receptor pathways.
13
There has been no integrative approach to elucidating the key
regulatory pathways. Importantly, we believe that, not only can
we uncover key molecular pathways, but we can also generate
gene signatures that are mechanistically coherentdor, in other
words, enriched for the same molecular pathways.
While past computational approaches in prostate cancer have
focused on ranking single gene targets among multiple diseases,
14
we hypothesized that, using protein interactions, we could take
advantage of the richness that gene signatures have to offer in the
selection of molecular pathways that play essential roles in
prostate cancer progression. To this end, we extracted a broad
representation of poor-prognosis gene expression prostate cancer
signatures from the literature (seed signatures). We then evalu-
ated their individual protein interactions with known cancer
genes curated by the Wellcome Trust Sanger Institute via SPAN.
We further assembled the signiﬁcant interactions of each
signature. The result is what we term an‘interactor signature’da
prioritized list of genes relating independent prostate cancer gene
signatures. We evaluated this interactor signature in two ways:
its internal mechanistic coherence using a novel application of
information theory similarity and then its intrinsic ability to
predict survival in a cohort independent of the seed signatures’
cohorts. Finally, we added a qualitative evaluation of the
signature against known prostate cancer pathways and current
therapies. Taken together, we show that, through an extensive
network analysis, prostate cancer gene expression signatures can
be transformed into a set of prioritized pathways that ultimately
provide a useful guide for therapeutic development.
METHODS
Datasets used
Prostate cancer signatures
We evaluated 12 previously published prostate gene signatures of
poor prognosis
15e27 and a previously unpublished prostate
cancer gene signature derived from a Mayo Clinic dataset
22 listed
in table 1. Thus a total of 13 gene signatures were evaluated.
Signatures were deliberately chosen to span various phenotypes
(eg, high-grade tumor, stem cell nature) but uniﬁed in their
ability to prognosticate either decreased overall survival or early
disease relapse in prostate cancer datasets. These distinct speciﬁc
phenotypic conditions are well-established biological or clinical
indicators of aggressive malignancy. A full listing of the genes
from the included prostate cancer signatures and their
translation are available at http://lussierlab.org/publications/
ProstateSignature.
Cancer mechanism genes
The Sanger Cancer Gene Census is a database maintained by the
Wellcome Trust Cancer Genome Project, which contains
a catalog of genes for which mutations have been causally
implicated in cancer, acquired and updated through literature-
based methods. We downloaded the Cancer Gene Census on
October 9, 2009 from http://www.sanger.ac.uk/genetics/CGP.
Proteineprotein interaction network
In brief, the protein interactions were downloaded from the
Search Tool for the Retrieval of Interacting Genes version 8.0 on
December 19, 2008 (STRING; http://string.embl.de).
29 STRING
is a repository maintained by a European consortium of
genomics facilities which contains known and predicted
proteineprotein interactions derived from such sources as high-
throughput experiments, co-expression data, and literature. We
extracted all human proteineprotein interactions and retained
those with a combined score of >900 (highly reliable score) that
also had gene fusion, experimental, or database evidence. Thus
text mining results of STRING were ﬁltered out. A total of
72617 distinct interactions between 7681 distinct proteins were
retained.
11 Proteins were considered to be nodes, and
interactions between proteins are links.
Signature generation from the Mayo Clinic prostate cancer data
The original Mayo Clinic signature was signiﬁcantly smaller
than other comparable signatures, and we thus recalculated
a broader signature as follows. Gene Expression Omnibus
(GSE10645) was downloaded and analyzed using R/Biocon-
ductor. We compared men who had biochemical relapse with
systemic disease (bone or visceral disease) with those who did
not. Genes with little to no change in expression levels were
ﬁltered using a covariance of expression parameter of 0.3.
Signiﬁcance analysis of microarrays
30 was then performed to
obtain a gene signature with a false discovery rate (FDR) <5%.
SPAN analysis of the prostate cancer gene signatures
The SPAN method has been extensively described previously,
9 11
and expanded details can be found in the online supplemental
methods. In brief, each prostate cancer gene signature was
compared with the Sanger Cancer Gene set using SPAN. The
observed number of interactions between the prostate cancer
signatures and the Sanger cancer genes were derived and
compared with an expected distribution through permutation
resampling. The unadjusted p value of each signature gene’s
connectivity was further adjusted for multiplicity using
Bonferroni-type methods. A converse calculation was performed
where each single Sanger cancer gene was analyzed for its total
number of interactions with each independent, unique gene in
the amalgamated prostate cancer signatures independently and
assigned a p value and a BenjaminieHochberg FDR. Prioritized
genes and their interactors that had a FDR <5% were retained.
The resulting statistically signiﬁcant genes were then aggregated
to form an ‘interactor signature’. As each SPAN protein keeps an
equal number of partners in the empirical distribution (constant
node degree), ‘hub proteins’ are statistically prioritized using
conservative controls. See ﬁgure 1 and the online supplemental
methods for details of interactor signature assembly from seed
signatures. The resulting network was then displayed in Cyto-
scape
31 where Sanger cancer genes that are also members of the
expression signature gene lists are clearly represented. Further,
when SPAN-prioritized Sanger cancer genes from individual
signature genes also overlap between these signatures, these
shared known cancer interactions common among signatures
serve as a ‘quasi-gold standard’ because of the very high
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Visualization of statistically signiﬁcant pathways using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) provided
a further unbiased evaluation of reference gold-standard
pathway genes and their associated networks.
32
Gene Ontology enrichment of the interactor signature
Using FuncAssociate 2.0 software,
33 we evaluated the resulting
interactor signature genes for common molecular processes and
biological functions from annotations found in Gene Ontology
(GO). GO annotations that were statistically over-represented
Table 1 Prostate cancer gene signatures evaluated
Signature No Phenotype Samples used to generate signature Author Available genes In Network*
1 Aggressive disease Divided 66 microdissected prostate
cancer specimens into two groups based
on clinical aggressiveness deﬁned as
prostate-speciﬁc antigen (PSA) relapse
following radical retropubic
prostatectomy (RRP), distant metastasis,
or cancer invasion into adjacent organs
Yu et al
28 26 Yes
2 Benign versus cancerous prostate tissue Proteomic screen of microdissected
prostate tissue embedded in tissue
microarray for genes that best
discriminated between benign, localized
prostate cancer and metastatic disease
Bismar et al
18 12 Yes
3 High-grade tumor Examined 12 microdissected RRP Gleason
pattern 3 specimens compared with that
of 12 Gleason pattern 4 and eight Gleason
pattern 5
True et al
27 85 Yes
4 PTEN pathway/poor prognosis Comparison of 35 phosphatase and tensin
homolog (PTEN) negative and 70 PTEN
positive based on immunohistochemistry
from stage II estrogen receptor status-
matched breast cancer specimens.
Signature subsequently validated in
a historic dataset of 79 prostate cancer
specimens
19 described above in the Sun
et al signature
Saal et al
24 184 Yes
5 Recurrence signature in solid tumors Comparison of gene expression signature
from 12 metastatic adenocarcinoma
nodules from prostate and ﬁve other
tissue types compared to 64 primary
adenocarcinomas from primary tumors
Ramaswamy et al
23 17 Yes
6 Recurrent/aggressive disease Evaluated 62 primary prostate tumors, 41
normal prostate specimens and nine
lymph node metastases to develop a two-
gene model of recurrence
Lapointe et al
21 2N o
7 Recurrent disease 79 patient RRP specimens from patients
with clinically localized prostate cancer.
39 cases with recurrence deﬁned as three
consecutive elevations in PSA for at least
5 years
Sun and Goodison
26 11 No
8 Recurrent disease Using 21 prostate cancer samples, ﬁve
genes using k-nn clustering were
identiﬁed.
Singh et al
25 5N o
9 Recurrent disease /High-Gleason score 512 candidate genes were analyzed for
correlation with Gleason score from 71
patient RRP specimens (16 patients with
relapsed disease deﬁned as two
consecutive PSA elevations over
84 months)
Bibikova et al
16 16 Yes
10 Relapse-free survival Using 21 prostate cancer samples from
Singh et al, the authors identiﬁed three
signatures of recurrence and
subsequently validated these signatures
on a set of 79 tumors
Glinsky et al
19 4/4/5 No
11 Stem cell nature Comparison of CD133
+/a2b1
hi cell culture
specimens from 12 human prostate
cancers compared with eight CD133
e/
a2b1
low specimens.
Birnie et al
17 22 Yes
12 Systemic disease after relapse, Sig 1 213 patients with prostate cancer PSA
relapse and no evidence of systemic
disease (deﬁned as a positive bone scan
or CT scan) were compared with 213
patients with prostate cancer with PSA
relapse
Nakagawa et al
22 17 No
13 Systemic disease after relapse, Sig 2 Reanalysis of the above Nagakawa et al
(Mayo Clinic dataset) as described in the
Methods section
133 Yes
*In Network indicates that the listed gene signature connects to the Sanger cancer genes via SPAN and composes part of the interactor signature.
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then used to identify more informative GO terms.
11
Evaluating pathway similarity among sets of gene signatures
In order to determine if sets of genes comprised related or
unrelated molecular pathways, we calculated a metric of infor-
mation theoretic similarity (ITS) applied to GO that we and
others have previously validated.
10 Among the approaches used
to estimate similarity between gene functions, those derived
from information theory and GO are considered robust and state
of the art,
34 and we have previously demonstrated their utility
in calculating the similarity between breast cancer expression
signatures.
9 We performed two evaluations using this metric.
First, we examined the similarity of annotations within each
seed signature geneset (lists of its genes) and the interactor
signature in the context of GO to derive an ITS score by
examining each geneegene distance using the information
theoretic distance. The information theoretic distance of each
geneegene distance was based on their respective annotations in
GO. We then took the summation of all the scores of the unique
gene pairs. We divided this total score by the number of genes in
the signature. These scores were not further normalized, as we
used an information theoretic distance, not the gene expression
level, between the genes. Information theoretic distances are
calculated as a continuous variable between 0 and 1. Therefore
all measurements are within the same scale, and in our esti-
mation did not require further normalization. Scores were
calculated for the interactor signature and for the original gene
signatures. To control the ITS for length of signature, we then
generated an empiric distribution by using a bootstrap,
Figure 1 Representative assembly of
the protein network from disparate gene
signatures. As shown in (A), signature
1 gene/proteins (blue circles) do not
connect directly with signature 2
proteins (green circles). Protein
interaction networks can independently
link (solid line) each gene signature to
a common set of cancer genes from the
Sanger database (red triangles in B).
Subsequently, using single protein
analysis of network (SPAN), only
proteineprotein interactions with
a false discovery rate (FDR) <0.05 are
retained in each signature and an
aggregate of interactors is assembled
from all SPAN analyses of each
signature, thus generating a composite
network with a FDR <1% ((C) large
shapes¼FDR <5%, small shapes¼FDR
>5%). Prognostic gene expression
signatures are represented as squares,
and their respective genes are related
with dotted lines.
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network for each signature; we selected the same number of
signature genes, calculated the ITS, and repeated this procedure
10000 times. We then observed the rank of the original gene
signature ITS score within the individual empirical distributions
and calculated a p value (reported in table 1).
Generation of a prioritized phenotypeepathway map
We examined the connectivity of the interactor signature to
itself using SPAN. Signiﬁcant proteins with a FDR <0.05 were
retained. We then overlaid KEGG pathway data on to the
resultant protein network using the DAVID tool
35 (adjusted
p value <0.05). The ﬁnal annotated protein network is what is
considered to be the phenotypeepathway map. This pathway
map has been thoroughly reviewed in the literature for its
biomolecular mechanistic relevance to prostate cancer progression
and prognosis.
Survival analysis
To test the clinical relevance of the interactor signature, we
examined its ability to ﬁnd a survival difference in a large and
independent retrospective dataset of 281 Swedish men who
underwent a course of ‘watchful waiting’ after being diagnosed
with prostate cancer (GSE10645).
22 This survival analysis using
a separate dataset serves as a type of clinical evaluation of the
interactor signature. This set of 281 only included patients who
were alive or had died from prostate-cancer-speciﬁc causes. For
each patient, gene expression levels from the interactor signature
were totaled to develop a per-patient score. Patients were placed
in one of two groups on the basis of whether or not they were
above or below the mean score. KaplaneMeier analysis was then
performed using time from diagnosis until death. In a second
analysis, only patients with undisputed disease (Gleason scores
of 7, 8, or 9) were included for analysis.
Qualitative validation of interactor genes, connections, and network
To establish whether the genes, interactions, and network
prioritized via our analyses were relevant in prostate cancer,
multiple reference sources were queried. (i) PubMed literature
searches restricted from 2000 to 2010 were entered with the
target genes and their interactions of interest and the keyword
‘prostate’. Relevant and high priority pathways were then
identiﬁed and reported. (ii) Genes were analyzed by Ingenuity
Pathway Analysis (Ingenuity Systems; http://www.ingenuity.
com) to observe literature-based connections among the genes
and canonical sub-networks. (iii) ClinicalTrials.gov website from
December 1, 2010 was queried for each SPAN prioritized gene in
the second interactor signature to observe whether relevant
clinical trials were ongoing or planned.
RESULTS AND DISCUSSION
Prostate cancer gene signatures are tightly interwoven and have
greater interacting partners than expected by chance
We began with 13 prostate cancer signatures that all had
statistically signiﬁcant worsened survival outcomes in indepen-
dent cohorts of patients with prostate cancer. Eight gene
signatures among the 13 met the compound connectivity
criteria of (i) FDR <5% and (ii) having two or more interactors
between the gene expression signature and the Sanger cancer
genes (Methods). Of note, traditional measures of prostate
cancer aggressiveness are based on the tumor morphology or
grade, and thus four of the signatures examined this speciﬁcally:
(i, ii) benign versus cancerous prostate tissue,
18 (iii) high-Gleason
score
16 and (iv) high-grade tumor.
27 Recurrent disease is by
deﬁnition already more aggressive, and multiple gene expression
proﬁles were derived from tumors with this phenotype: (v, vi,
vii) recurrent disease,
19 25 26 (viii) recurrence signature in solid
tumors,
23 (ix, x) systemic disease after relapse
22 and recalculated
systemic disease after relapse (Mayo Clinic dataset), and (xi)
aggressive diseasedwhich included patients who relapsed after
primary therapy.
28 The last two signatures are based on princi-
ples of the cancer biology of aggressivenessdnamely more
primitive appearing cancersd(xii) stem cell in nature
17 or
cancers that have a known phosphatase and tensin homolog
(PTEN) deregulation (xiii) PTEN pathway.
24 Please refer to
table 1 for full details.
Using SPAN methodology, we evaluated whether any genes
from the prostate cancer gene signatures that were signiﬁcantly
connected to the Sanger cancer genes curated by the Wellcome
Trust Cancer Genome. We also examined whether there were
Sanger genes that were signiﬁcantly connected to each gene
signature. In total, 42 genes were statistically signiﬁcant with
a FDR of 5% and met criteria for having at least two interacting
partners (table 1, online supplemental table 1). We call these 42
genes the ‘interactor signature’. Eight of the 13 gene signatures
were connected via SPAN.
We also examined the interactor signature genes’ connectivity to
other genes. As a check of our prioritization method, we believed
t h a to u ri n t e r a c t o rg e n e sw o u l dh ave importance within a network
context. To conﬁrm this, we relied on work published by the
Gerstein laboratory,
36 who had identiﬁed speciﬁcn e t w o r kp r o t e i n s
as having biologically signiﬁcant properties. They deﬁned ‘hubs’ as
proteins that have the 20% highest number of neighbors, and
‘bottlenecks’ as the proteins that are in the top 20% in terms of
betweenness (connecting groups of proteins). In our network, 29
(69%) proteins were bottlenecks, 25 (59%) were hubs, and 24 (57%)
were both bottleneck and hubs (online supplemental table 1).
SPAN analyses are conservatively controlled for hubness. Each
protein keeps its node degree (number of protein interactions)
constant in each permutation, while its interactors are resampled.
The fact that 57% were both hub and bottleneck proteins is in far
e x c e s so ft h eb a s e l i n e1 0 . 1 4 %i narandom distribution of proteins
from the network (p<0.0001, Fisher exact test).
36 This conﬁrmed
to us that, at a network structure level, our interactor signature
identiﬁed critical players in poor-prognosis prostate cancer. The
tightly interwoven nature of our interactor signature is readily
evident in our graphical representation of its relationships (ﬁgure 2).
Interactor signature genes are involved in cell cycle, PDGF and
ﬁbroblast growth factor (FGF) signaling, and phosphorylation
We sought to characterize the predominant biomolecular func-
tions of the selected 42 genes. To do this, we evaluated the
functional annotations found in GO of this interactor signature.
GO is essentially a hierarchical lexicon of terms used to describe
genes. We determined whether these descriptors of biomolecular
functions were enriched in our gene set. Highly signiﬁcant
(adjusted p value <0.0001) descriptors that were associated with
this set of genes were terms related to several pathways, namely
PDGF and FGF signaling. Also notable were annotations related
to cell cycle regulation and phosphorylation. Full results of this
GO enrichment are listed in online supplemental table 2.
The 42-gene interactor signature prioritizes key pathways better
than other prostate gene signatures
To evaluate whether the genes in our interactor signature were
more related to one another (ie, involved in the same molecular
pathway or performed the same molecular function) than genes
396 J Am Med Inform Assoc 2011;18:392e402. doi:10.1136/amiajnl-2011-000178
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of evaluating the similarity of genes based on their shared
annotation in GO.
11 We computed an ITS score, which
evaluates the average similarity of a set of genes. Using this
algorithm, we systematically evaluated the ITS between each
pair of signatures including the 42-gene interactor signature and
the 13 original prostate cancer gene signatures. Next, to correct
for gene signature length and to calculate an empiric p value,
we generated 10000 bootstraps of a similar length gene
signature derived from the protein network and then examined
the rank of each gene signature among the bootstraps. The
interactor signature ranked ﬁrst in 10000 bootstraps
(p#0.0001) of a similar number of genes as demonstrated by
table 2. The only other signature that was statistically
signiﬁcant was Bibikova’s high-Gleason signature, which
resulted in a signiﬁcant but lower p value of 0.017.
The SPAN-generated interactor signature has prognostic
signiﬁcance in newly diagnosed prostate cancer
To evaluate the clinical relevance of the interactor signature,
we performed our evaluation in a completely independent
dataset, the Swedish Watchful Waiting Cohort.
37 In this study,
281 men underwent a course of watchful waiting after diag-
nosis of prostate cancer. We asked whether interactor signature
overexpression was able to distinguish a group with poorer
survival. Of the genes in the interactor signature, 35 were
available for analysis. We divided the patients into two groups
on the basis of whether their mean gene expression was higher
t h a nt h ea v e r a g eo ft h ee n t i r ec o h o r t .K a p l a n eMeier survival
analysis of the two groups from the date of their diagnosis was
performed. The log rank test gave a p value that approached
signiﬁcance at 0.052. Importantly, given the heterogeneity
of prostate cancer, we were able to detect an even greater
signiﬁcance (p¼0.009) when we only evaluated a subset of 198
patients with high-grade prostate cancer (Gleason 7e10)
(ﬁgure 3).
SPAN analysis of the interactor signature emphasizes pathways
of prostate cancer progression
Our ﬁrst SPAN analysis generated a set of highly connected
genes (interactor signature) related to prostate cancer. A second
SPAN analysis over the interactor signature allows us to
prioritize molecular pathways vis-à-vis their protein interactions
with one another. In other words, the ﬁrst SPAN allowed us to
identify disparate expression signatures interacting with
common cancer proteins of the gold standard Sanger cancer
genes (Methods). For the 42 key protein interactors thus
generated, we then further annotated the most central ones in
the network. The determination of centrality was performed via
a second SPAN analysis over the interactor signature proteins
that resulted in their prioritization (node size) and clariﬁcation
of their interactions as shown in ﬁgure 4. To highlight estab-
lished pathways, we overlaid canonical pathway information
from the KEGG
32 after calculating which of the pathways were
represented at a statistically signiﬁcant level (p<0.05). The
result, when graphed, is what we call a phenotypeepathway
map (ﬁgure 4). In this prostate cancer phenotypeepathway map
of poor prognosis, seven of the original prostate cancer gene
signatures form coherent subgroups that are consistent with
established pathways.
Our second SPAN and resulting prostate phenotypeepathway
map allows us to better understand the biological meaning of
the interactor signature. By looking for dominant molecular
mechanisms and highly connected genes, we can begin to
untangle, and conjecture about, the key pathways of poor-
prognosis prostate cancer.
Figure 2 Combined network of
prioritized signature genes and cancer
proteins derived from single protein
analysis of network (SPAN) protein
interaction analysis conducted over
each expression signature. Prostate
cancer gene signatures of poor
prognosis (large grey squares) were
evaluated for their proteineprotein
interaction connectivity to the Sanger
cancer genes curated by the Wellcome
Trust Cancer Gene Atlas through SPAN
methodology. Squares represent
prostate cancer gene signatures, circles
indicate network genes, and triangles
indicate Wellcome Trust Sanger cancer
genes. Red indicates statistically
signiﬁcant proteins (false discovery rate
(FDR) <5%) with at least two
interacting partners, and grey indicates
non-prioritized proteins. Nodes on the
outer circle indicate prostate cancer
signature genes, and nodes in the
innermost circle indicate proteins
contributing to prioritize the statistically
signiﬁcant ones but for which the FDR
>5%. Dashed lines indicate linkages
between signature genes and their
respective signatures, and solid lines
indicate a protein interaction.
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phosphatidylinositol-3 kinase (PI3K)/NF-kB centrality to prostate
cancer progression and highlights driver pathways
Examining ﬁgure 4 in detail, we can see that the PI3K/NF-k B
signaling cascade is central to this phenotypeepathway map, as
it is a common end point for the various upstream signaling
cascades. The role of the PI3K/NF-kB in prostate cancer
progression is well established and is believed to be a mechanism
for cross-talk with the androgen receptor and thus is implicated
in androgen independence.
38 This ﬁnding has been noted in
prostate cancer by multiple observers.
39 As in the following
qualitative discussion, we can recapitulate and prioritize major
drivers of poor-prognosis prostate cancer, as well as describe
under-reported ﬁndings. As shown below in our review of the
literature, the Janus kinase 2 (JAK2) and STAT1 stories were
perhaps the most novel and under-reported.
Feeding into the PIK3/NF-kB pathway are driver pathways
that include
1 the PDGF signaling cascade,
2 FGF signaling,
3
interferon (IFN)g signaling, and
4 the JAK/STAT pathway. When
we consider the KEGG annotations of the pathways, we observe
that the pathway ‘regulation of actin cytoskeleton’ (hsa:04010)
encompasses FGF and PDGF signaling through the PI3K/NF-kB
cascade. A second KEGG pathway, JAK/STAT (hsa: 04630),
captures IFN signaling. The importance of the JAK/STAT
pathways is consistent with conclusions in a separate paper
analyzing molecular proﬁling of prostate cancer stem cells.
17
Key regulators of cell cycle derangements constitute
a substantial portion of the phenotypeepathway map
Consistent with the established role of PI3K/NF-kB in mitogenic
activation, downstream proteins were nearly all associated with
the cell cycle (hsa: 04110) (ﬁgure 4B). Cell cycle kinases, regu-
latory proteins and proliferating cell nuclear antigen, a known
marker of proliferation,
40 constitute the majority of the identi-
ﬁed proteins. Cyclin D3 (CCND3) and its ligand, the tumor
suppressor protein retinoblastoma 1 (RB1), were prioritized as
part of cell cycle regulation. RUNX1dnormally associated with
acute myeloid leukemia (AML)dwas tightly associated with
this sub-network as well. Previous work has demonstrated that
RUNX1 cooperates with E-twenty six transcription to activate
transcription in the setting of androgen deprivation.
41
JAK2 is uniquely positioned in the phenotypeepathway map as
an activator of the PI3K/NF-kB cascade
Perhaps most interesting from a translational medicine
perspective is the utility of the phenotypeepathway map in
helping identify key genetic lynchpins. JAK2 is involved in
cytokine receptor signaling and has been experimentally
conﬁrmed in prostate cancer.
12 Examination of ﬁgure 4A reveals
that JAK2 is connected either directly or indirectly to nearly all
the proteins that are upstream of the PI3K/NF-kB signaling
cascade. We note the interplay of JAK2 with the FGF, PDGF and
IFN pathways. Indeed, phosphorylation of the Stat3 oncogene
via the FGF pathway is dependent on JAK2.
42 The Stat3 onco-
gene in turn is believed to be downstream of PDGF and also
activated via JAK2.
43 PDGF activation can then proceed through
the PI3K/NF-kB pathway
44 to activate proliferation. Similarly,
the proinﬂammatory cytokine, IFNg, is traditionally thought to
bind to the IFNg receptor (partly encoded by IFNGR1) and then
act via the JAK2/STAT1 pathway in a tumor suppressor role in
Figure 3 KaplaneMeier analysis of the 42-gene interactor signature
revealed a clinically signiﬁcant signal. Genes from the interactor
signature that were available for analysis (35 genes total) from an active
surveillance study of prostate cancer were used for analysis. 198
patients with high-grade (Gleason 7e10) disease were used, and overall
survival from time of diagnosis was determined. The log rank test
showed a signiﬁcant survival difference in patients who had higher
average expression levels of the genes of interest versus those who had
lower average expression (p¼0.009; KaplaneMeier analysis). Asterix
(*) indicates lower expression of interactor signature.
Table 2 Signiﬁcance of pathway similarity among sets of gene signatures
Signature
number Signature name p Value
Rank among 10000 gene
length identical bootstraps Phenotype
Na Interactor signature #0.0001 1 Na
9 Bibikova 0.017 174 Recurrent disease/high-Gleason
10 Glinsky 3 0.070 701 Relapse-free survival
12 Nakagawa 0.086 858 Systemic disease after relapse
6 Lapointe 0.114 1146 Recurrent/aggressive disease
5 Ramaswamy 0.173 1728 Recurrence signature in solid tumors
13 Mayo Clinic dataset 0.309 3091 Relapse-free survival
1 Yu 0.344 3440 Aggressive disease
4 Saal 0.452 4520 PTEN pathway/poor prognosis
7 Sun 0.452 4520 Recurrent disease
10 Glinksy 2 0.463 4632 Relapse-free survival
3 True 0.519 5186 High-grade tumor
8 Singh 0.523 5233 Recurrent disease
10 Glinsky 1 0.538 5382 Relapse-free survival
2 Bismar 0.652 6615 Benign versus cancerous prostate tissue
11 Birnie 0.887 8874 Stem cell nature
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Research and applicationsFigure 4 Prostate phenotypeepathway map. A second single protein analysis of network (SPAN) was conducted over the network presented in
ﬁgure 2 to prioritize a subset of the 42-gene interactor prostate signature of poor prognosis which revealed a tightly interwoven network (top panel;
Methods). Proteins with an empiric false discovery rate (FDR) <0.05 were retained and are indicated by the larger size shape. Signiﬁcant KEGG
pathways (FDR <0.05) were overlaid on to the network and colorized as indicated. Detail A and Detail B expand areas in the top panel that were
simpliﬁed. Square shapes denote prognostic expression signatures with dotted lines to their associated gene; hexagons represent several proteins
that are closely associated with one another and combined for purposes of simplicity of representation; triangles denote Sanger genes as compared
with circle shapes which denote the protein products of signature genes.
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45 In fact, STAT1 activation may be a marker of
derangement in the sensitivity in IFN signaling and has been
associated with chemoresistance in the castrate setting.
46 In
other work, Gu et al have published a series of papers charac-
terizing the behavior of STAT3 and STAT5a/b transcription
factors using in vivo and in vitro models, and recently posited
whether JAK2 is the ‘common denominator’ for their dual
activation in clinical prostate cancers.
12 Thus the prostate
phenotypeepathway map highlights the centrality of JAK2 as
a mediator of the prioritized pathways. Whether JAK2 inhibi-
tion alone is sufﬁcient to prevent the recurrence of prostate
cancer or is a bona ﬁde therapeutic target for advanced disease
remains to be determined in clinical trials.
Bioinformatics can provide an ‘executive synopsis’ of relevant
molecular pathways and points to potential drug targets
This is the second study that conﬁrms mechanistic overlap in
relatively disjointed but prognostically congruent gene signatures,
a paradox noted by Joan Massague in 2007,
8 that was solved with
our previous publication.
9 We initially demonstrated that cancer
genes, both oncogenes and tumor suppressors, were interacting
with signature genes more than expected by empirical distribu-
tion in our network modeling of protein interactions. Although
our previous study was conducted in the breast domain, this
study corroborates our previous ﬁndings in the prostate arena but
differs in two ways. First, we ensure the biological signiﬁcance of
our ﬁndings by introducing an information theory-based metric.
Second, we provide a completely unbiased patient cohort to
conﬁrm the clinical relevance of our study.
In this paper, we demonstrate, through established bioinfor-
matics methods, that we can transform heterogeneous and
complex prostate cancer gene signatures of poor prognosis into
a clinically meaningful ‘executive synopsis’ of the most relevant
pathways and critical genes such as JAK2. There are undoubt-
edly many such genes. Table 3 provides a summary of the
members of the phenotypeepathway and their exploration as
potential therapies. A comparison list of drugs and drug targets
derived from KEGG can be found in online supplemental table 3.
As shown, these in silico results mirror relevant prostate cancer
pathways that have been found and veriﬁed experimentally in
vitro/in vivo.
We also learned that the best discriminatory genes for an
expression signature do not necessarily make the best input into
the SPAN network. The 17-gene Nakagawa signature, which
was developed using a non-parametric supervised learning
method, ultimately did not connect to the network. In contrast,
a 132-gene signature derived in an unbiased manner from the
same dataset connected to nearly all the other signatures via
SPAN. Thus genes that have the greatest degree of discrimina-
tory ability may indeed be ‘passenger’ genes rather than ‘driver’
genes. For purposes of SPAN analysis, we believe it is better to
pursue the most unbiased gene signature to identify a larger
grouping of statistically relevant genes and allow the protein
network to perform the ﬁltering. In other words, a larger set of
genes is more likely to comprise the ‘drivers’ of cancer mecha-
nisms from which SPAN can assert protein interactions, rather
than the ‘passenger’ genes that simply correlate with outcome
and thus cannot contribute mechanisms in network models.
LIMITATIONS
By design, we used a simple, single protein network interaction
model to calculate p values, as it is easier to interpret signiﬁcant
results by clinicians and biologist. However, more sensitive and
powerful network modeling is likely to yield additional insight,
such as diffusion kernels.
59 Furthermore, we conducted the
analysis using STRING version 8.0, which contains a limited
number of interactions and thus limited the study to this subset
of proteins. While the computational controls show that the
observed network signature is highly statistically signiﬁcant, the
qualitative evaluation of the results rely on previously published
data. We are therefore beholden to the different methodologies
and the multitude of oligonucleotide arrays used to derive the
gene signatures. We have attempted to overcome this by care-
fully incorporating multiple independent gene signatures and
using stringent statistical cut-offs to ensure a conservative
evaluation. Indeed, each seed signature SPAN analysis required
an FDR <0.05 and more than one interactor; this suggests that
the relevant interactors of this network signature (spanning
multiple seed signatures) more likely have a signiﬁcance of FDR
<<0.05. Additionally, the KaplaneMeier analysis was
performed in a completely independent dataset of all the
signatures and therefore provided an unbiased evaluation.
The protein-interaction network and the Sanger cancer genes
are not static but vibrant growing entities. As we learn more
about factors contributing to prostate cancer, undoubtedly there
will be additions and variations to the phenotypeepathway
map. Nevertheless, the intent of this study was to provide and
explore a tool for understanding gene expression signatures
quickly at this moment in time. Going forward, we do intend to
rerun these analyses with updated and expanded lists of gene
signatures. Furthermore, as we have shown that different
interactors prioritized in distinct seed signatures may be related
to the same oncogene by interactions, this fact suggests that
novel methods should be developed to produce expression clas-
siﬁers where the interaction is investigated ab initio rather than
a posteriori. Such an approach could be designed to identify,
across samples, signiﬁcant, yet distinct, interactors to an onco-
gene, thus promoting within the principles of personal genomics
a fundamental paradigm shift from the current cohort-wide
requirements.
Table 3 Phenotypeepathway map genes and their stage of clinical
drug development within prostate cancer (source: http://ClinicalTrials.
gov and PubMed data as of December 2010)
Prioritized gene
Relation to
prostate cancer
Signature or
cancer gene
Clinical drug
development
CCND3 Established
47 Both No data
CDK(4/6/7) Well-established
48 Cancer/cancer/
signature
Yes
CDKN1C Well-established
49 Signature Tumor suppressor
CDKN(2A/2B/2C) Established
50 Cancer/signature/
signature
Tumor suppressor
E2F1 Well-established
51 Signature No data
FGF(1/2),
FGFR(1/3)
Well-established
42 Signature/signature/
both/cancer
Yes
HDAC1 Well-established
52 Signature Yes
IFNGR1 Established
53 Signature No data
ITGAV Established
54 Signature No data
JAK2 Well-established
55 Both Yes
NFKB1 Well-established
56 Signature Yes
PCNA Well-established
40 Signature No data
PDGF(A/B),
PDGFR(A/B)
Well-established
13 Signature/both/
both/both
Yes
PI3KR1/PI3KCA Well-established
38 Both/cancer Yes
RB1 Well-established
57 Cancer Tumor suppressor
RUNX1 Established
58 Both No data
STAT1 Role unclear
46 Signature No data
SUZ12 No data Cancer Yes
PCNA, proliferating cell nuclear antigen.
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Research and applicationsIn summary, the phenotypeepathway map provides an
excellent starting point for developing rational clinical trial
designs, as it can inform researchers about what therapy should
be attempted ﬁrst that may be helpful for the largest number of
patients. To this end, we are working on translating our priori-
tized pathway ﬁndings into the clinical setting; simultaneously,
we are extending this technique to other tumor types. As more
knowledge accumulates about oncogenes and gene signatures,
reanalysis by this technique may reveal new pathways and
interconnections that were heretofore unknown or understudied.
CONCLUSION
By analyzing multiple prostate cancer signatures of poor prog-
nosis, we have uncovered seven highly connected cancer genes
that were not among our original gene signatures of poor
prognosis. This further conﬁrms our hypothesis that, while
multiple genes in a high-throughput analysis may change along
with the activity of oncogenes or tumor suppressors, the critical
information contained in direct physical interactions among
proteins is not accessible via expression arrays. As a result,
a multiscale approach incorporating gene expression data and
protein interaction networks can elucidate otherwise neglected
targets and underlying molecular sub-networks underpinning
the phenotypic concordance of genetically disparate gene
signatures. At the gene expression signature level, the pathways
are not apparent. However, the interactor signature not only
prioritizes biological mechanisms underpinning multiple signa-
tures, it also recapitulates in good part known pathways
involved in prostate cancer oncogenesis. Indeed, the phenoty-
peepathway map generated by our interactor signature truly
recapitulates and underscores the centrality of the PI3K/NF-kB
pathway and other known mechanisms for prostate cancer
progression. Moreover, through a systems biology approach, we
are able to prioritize less well-established pathways, such as
JAK2, that may ultimately serve as attractive drug targets. From
seed signatures generated at the cohort level, we have demon-
strated a posteriori that expression changes in direct, yet
distinct, interactors to oncogenes correlate with prognosis. Thus
we propose that ab initio design of mechanistically anchored
gene expression classiﬁers are more likely than current cohort-
level classiﬁer approaches to be sensitive to individual variation
in personal genomics.
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